First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 15 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR Daughter And Her Terminally Ill Dad Go On Bucket List Adventures... January 24, 2022 News digest – HPV vaccine, 1 million breast screenings missed and... October 3, 2020 Treatment Strategy for ecDNA-Driven Tumors Shows Potential December 5, 2024 Allergan Recalls Textured Breast Implants Worldwide Due To Cancer Risk At... July 24, 2019 Load more HOT NEWS This Amazing Woman Can Smell Alzheimer’s, Parkinson’s, and Cancer Years Before... Study Finds Accelerated Partial-Breast Radiation Just as Effective as Whole Breast... A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond...
